(Q34239910)

31 July 2017

1 reference

title

Current role of beta-adrenergic blockers in the management of chronic heart failure (English)

1 reference

31 July 2017

1 reference

chronic heart failure

1 reference

M Packer

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

American Journal of Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

110 Suppl 7A

1 reference

31 July 2017

page(s)

81S-94S

1 reference

Plasma norepinephrine in congestive heart failure

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Pathophysiology of chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Inotropic and calcium kinetic effects of calcium channel agonist and antagonist in isolated cardiac myocytes from cardiomyopathic hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

β-Adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Significance of myocardial alpha- and beta-adrenoceptors in catecholamine-induced cardiac hypertrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

The role of alpha-adrenoceptors in the regulation of renal tubular sodium reabsorption and renin secretion in the rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Renal nerve stimulation causes alpha 1-adrenoceptor-mediated sodium retention but not alpha 2-adrenoceptor antagonism of vasopressin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Influence of isoproterenol on myocardial energetics. Experimental and clinical investigations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Coronary vasoconstriction and catecholamine cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Epinephrine-induced hypokalemia: the role of beta adrenoceptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

An alpha-1-adrenergic receptor subtype is responsible for delayed afterdepolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Altered myocardial force-frequency relation in human heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Adrenergic effects on the biology of the adult mammalian cardiocyte

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Nebivolol increases survival in cardiomyopathic hamsters with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Contribution of alpha-adrenoceptor activation to the pathogenesis of norepinephrine cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Alpha 1-adrenoceptor activity in arterial smooth muscle following congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Cardiac effects of beta-adrenoceptor antagonists with intrinsic sympathomimetic activity in humans: beta1- and/or beta2-adrenoceptor mediated?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Selectivity of the intrinsic sympathomimetic activity of the beta-adrenergic blocking drug bucindolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Double-Blind, Placebo-Controlled Study of the Long-term Efficacy of Carvedilol in Patients With Severe Chronic Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

The effect of digoxin on mortality and morbidity in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900676-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(01)00676-3

1 reference

31 July 2017

1 reference